Anderson, K. G., Oda, S. K., Bates, B. M., Burnett, M. G., Rodgers Suarez, M., Ruskin, S. L., & Greenberg, P. D. (2022). Engineering adoptive T cell therapy to co-opt Fas ligand-mediated death signaling in ovarian cancer enhances therapeutic efficacy. Journal for immunotherapy of cancer, 10(3), e003959. https://doi.org/10.1136/jitc-2021-003959
Citácia podle Chicago (17th ed.)Anderson, Kristin G., Shannon K. Oda, Breanna M. Bates, Madison G. Burnett, Magdalia Rodgers Suarez, Susan L. Ruskin, a Philip D. Greenberg. "Engineering Adoptive T Cell Therapy to Co-opt Fas Ligand-mediated Death Signaling in Ovarian Cancer Enhances Therapeutic Efficacy." Journal for Immunotherapy of Cancer 10, no. 3 (2022): e003959. https://doi.org/10.1136/jitc-2021-003959.
Citácia podľa MLA (8th ed.)Anderson, Kristin G., et al. "Engineering Adoptive T Cell Therapy to Co-opt Fas Ligand-mediated Death Signaling in Ovarian Cancer Enhances Therapeutic Efficacy." Journal for Immunotherapy of Cancer, vol. 10, no. 3, 2022, p. e003959, https://doi.org/10.1136/jitc-2021-003959.